Hammes, Jochen, Bischof, Gerard N., Bohn, Karl P., Onur, Oezguer, Schneider, Anja ORCID: 0000-0001-9540-8700, Fliessbach, Klaus, Hoenig, Merle C., Jessen, Frank, Neumaier, Bernd ORCID: 0000-0001-5425-3116, Drzezga, Alexander ORCID: 0000-0001-6018-716X and van Eimeren, Thilo ORCID: 0000-0002-6951-2325 (2021). One-Stop Shop: F-18-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. J. Nucl. Med., 62 (2). S. 240 - 247. RESTON: SOC NUCLEAR MEDICINE INC. ISSN 1535-5667
Full text not available from this repository.Abstract
Tau protein aggregations are a hallmark of amyloid-associated Alzheimer disease and some forms of non-amyloid-associated frontotemporal lobar degeneration. In recent years, several tracers for in vivo tau imaging have been under evaluation. This study investigated the ability of F-18-flortaucipir PET not only to assess tau positivity but also to differentiate between amyloid-positive and-negative forms of neurodegeneration on the basis of different F-18-flortaucipir PET signatures. Methods: The F-18-flortaucipir PET data of 35 patients with amyloid-positive neurodegeneration, 19 patients with amyloidnegative neurodegeneration, and 17 healthy controls were included in a data-driven scaled subprofile model (SSM)/principal-component analysis (PCA) identifying spatial covariance patterns. SSM/PCA pattern expression strengths were tested for their ability to predict amyloid status in a receiver-operating-characteristic analysis and validated with a leave-one-out approach. Results: Pattern expression strengths predicted amyloid status with a sensitivity of 0.94 and a specificity of 0.83. A support vector machine classification based on pattern expression strengths in 2 different SSM/PCA components yielded a prediction accuracy of 98%. Anatomically, prediction performance was driven by parietooccipital gray matter in amyloid-positive patients versus predominant white matter binding in amyloid-negative patients. Conclusion: SSM/PCA-derived binding patterns of F-18-flortaucipir differentiate between amyloid-positive and-negative neurodegenerative diseases with high accuracy. F-18-flortaucipir PET alone may convey additional information equivalent to that from amyloid PET. Together with a perfusion-weighted early-phase acquisition (F-18-FDG PET-equivalent), a single scan potentially contains comprehensive information on amyloid (A), tau (T), and neurodegeneration (N) status as required by recent biomarker classification algorithms (A/T/N).
Item Type: | Journal Article | ||||||||||||||||||||||||||||||||||||||||||||||||
Creators: |
|
||||||||||||||||||||||||||||||||||||||||||||||||
URN: | urn:nbn:de:hbz:38-596681 | ||||||||||||||||||||||||||||||||||||||||||||||||
DOI: | 10.2967/jnumed.120.244061 | ||||||||||||||||||||||||||||||||||||||||||||||||
Journal or Publication Title: | J. Nucl. Med. | ||||||||||||||||||||||||||||||||||||||||||||||||
Volume: | 62 | ||||||||||||||||||||||||||||||||||||||||||||||||
Number: | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||
Page Range: | S. 240 - 247 | ||||||||||||||||||||||||||||||||||||||||||||||||
Date: | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||
Publisher: | SOC NUCLEAR MEDICINE INC | ||||||||||||||||||||||||||||||||||||||||||||||||
Place of Publication: | RESTON | ||||||||||||||||||||||||||||||||||||||||||||||||
ISSN: | 1535-5667 | ||||||||||||||||||||||||||||||||||||||||||||||||
Language: | English | ||||||||||||||||||||||||||||||||||||||||||||||||
Faculty: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||
Divisions: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||
Subjects: | no entry | ||||||||||||||||||||||||||||||||||||||||||||||||
Uncontrolled Keywords: |
|
||||||||||||||||||||||||||||||||||||||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/59668 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |